[go: up one dir, main page]

SMT202100082T1 - Composti eteroarilici per il trattamento di malattie oftalmiche - Google Patents

Composti eteroarilici per il trattamento di malattie oftalmiche

Info

Publication number
SMT202100082T1
SMT202100082T1 SM20210082T SMT202100082T SMT202100082T1 SM T202100082 T1 SMT202100082 T1 SM T202100082T1 SM 20210082 T SM20210082 T SM 20210082T SM T202100082 T SMT202100082 T SM T202100082T SM T202100082 T1 SMT202100082 T1 SM T202100082T1
Authority
SM
San Marino
Prior art keywords
treatment
ophthalmic diseases
heteroaryl compounds
heteroaryl
compounds
Prior art date
Application number
SM20210082T
Other languages
English (en)
Inventor
Yoshihiro Banno
Masahiro Kamaura
Kazuaki Takami
Koichiro Fukuda
Shigekazu Sasaki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of SMT202100082T1 publication Critical patent/SMT202100082T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
SM20210082T 2014-10-24 2015-10-22 Composti eteroarilici per il trattamento di malattie oftalmiche SMT202100082T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014217770 2014-10-24
EP15853151.7A EP3210973B1 (en) 2014-10-24 2015-10-22 Heteroaryl compounds for the treatment of ophthalmic diseases
PCT/JP2015/079782 WO2016063933A1 (ja) 2014-10-24 2015-10-22 複素環化合物

Publications (1)

Publication Number Publication Date
SMT202100082T1 true SMT202100082T1 (it) 2021-03-15

Family

ID=55760964

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20210082T SMT202100082T1 (it) 2014-10-24 2015-10-22 Composti eteroarilici per il trattamento di malattie oftalmiche

Country Status (38)

Country Link
US (4) US10214498B2 (it)
EP (2) EP3210973B1 (it)
JP (2) JP6588027B2 (it)
KR (1) KR102490156B1 (it)
CN (2) CN115197160A (it)
AR (1) AR104342A1 (it)
AU (2) AU2015336480B2 (it)
BR (1) BR112017007138A2 (it)
CA (1) CA2965465C (it)
CL (1) CL2017000944A1 (it)
CO (1) CO2017003699A2 (it)
CR (1) CR20170160A (it)
CY (1) CY1123842T1 (it)
DK (1) DK3210973T3 (it)
DO (1) DOP2017000098A (it)
EA (1) EA033446B1 (it)
EC (1) ECSP17026687A (it)
ES (1) ES2848999T3 (it)
HR (1) HRP20210320T1 (it)
HU (1) HUE053443T2 (it)
IL (2) IL285105B2 (it)
LT (1) LT3210973T (it)
MA (2) MA39688B1 (it)
MX (2) MX2017004629A (it)
MY (1) MY183209A (it)
PE (1) PE20170669A1 (it)
PH (1) PH12017500747B1 (it)
PL (1) PL3210973T3 (it)
PT (1) PT3210973T (it)
RS (1) RS61504B1 (it)
SG (1) SG11201702312UA (it)
SI (1) SI3210973T1 (it)
SM (1) SMT202100082T1 (it)
TN (1) TN2017000097A1 (it)
TW (2) TWI703131B (it)
UA (1) UA121871C2 (it)
WO (1) WO2016063933A1 (it)
ZA (1) ZA201703344B (it)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201702312UA (en) * 2014-10-24 2017-05-30 Takeda Pharmaceuticals Co Heterocyclic compound
WO2018175385A1 (en) 2017-03-20 2018-09-27 The Broad Institute, Inc. Compounds and methods for the treatment of parasitic diseases
EP3638239A4 (en) 2017-06-15 2021-03-10 Belite Bio, Inc METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH RBP4 USING TRIAZOLOPYRIDINES
WO2018232154A1 (en) * 2017-06-15 2018-12-20 Belite Bio, Inc Methods of treating metabolic diseases with fused bicyclic pyrazoles
CN112512521A (zh) * 2018-08-01 2021-03-16 纽约市哥伦比亚大学理事会 用于治疗和预防非酒精性脂肪肝疾病和痛风的rbp4拮抗剂
CN111690698A (zh) * 2020-05-19 2020-09-22 浙江工业大学 两步串联流动合成3-（苯并[d][1,3]二氧-5-氨基）丙羟肟酸的方法
CN111690695A (zh) * 2020-05-19 2020-09-22 浙江工业大学 3-苯氨基丙羟肟酸的酶促微流控在线合成方法
US20240248099A1 (en) * 2021-05-21 2024-07-25 Belite Bio, Llc Biomarkers for age-related macular degeneration
WO2022256301A1 (en) * 2021-06-01 2022-12-08 Stargazer Pharmaceuticals, Inc. Methods and compounds for treating subjects with stargardt disease
CN116286900B (zh) * 2022-10-28 2024-04-26 昆明理工大学 一种乙酸渗透酶A基因RkAcpa及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625970A (en) 1968-04-17 1971-12-07 Cutter Lab 1-(disubstituted phenyl or benzyl)-1h-indazol-3-yloxyacetic acid
US5239080A (en) 1989-02-08 1993-08-24 Takeda Chemical Industries, Ltd. Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents
EP0440183A1 (en) * 1990-02-01 1991-08-07 Takeda Chemical Industries, Ltd. Oxazole compounds, their production and use
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
WO1999022735A1 (en) 1997-10-30 1999-05-14 Merck & Co., Inc. Somatostatin agonists
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
AU7556800A (en) 1999-10-07 2001-05-10 Tadeka Chemical Industries, Ltd. Amine derivatives
IL149493A0 (en) 1999-11-10 2002-11-10 Takeda Chemical Industries Ltd 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
GB0020351D0 (en) 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases
DE10149568A1 (de) 2001-10-08 2003-04-24 Consequence Gmbh Verfahren zur Sequenzanalyse von Polypeptiden
EP1437351A4 (en) 2001-10-19 2005-06-01 Takeda Pharmaceutical AMIN DERIVATIVE
US20040214788A1 (en) 2003-03-11 2004-10-28 Raj Madhwa H.G. Treatment of prostate cancer
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
CA2532026C (en) 2003-08-20 2012-04-17 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
US7553631B2 (en) 2003-12-11 2009-06-30 Beth Israel Deaconess Medical Center, Inc. RBP4 in insulin sensitivity/resistance, diabetes, and obesity
US7838561B2 (en) 2004-06-14 2010-11-23 Wisconsin Alumni Research Foundation Method for preventing or treating cardiac hypertrophy
ATE404188T1 (de) 2004-06-23 2008-08-15 Sirion Therapeutics Inc Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten
EP1768656A4 (en) 2004-07-22 2008-01-23 Vanda Pharmaceuticals Inc TREATMENT OF OCULAR DISEASES
WO2006042252A2 (en) 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
JP2009541357A (ja) 2006-06-22 2009-11-26 シリオン セラピューティクス， インコーポレイテッド メガリン活性の調節を介した眼科的状態を処置するための方法および組成物
KR20100037047A (ko) 2007-06-26 2010-04-08 렉시컨 파마슈티컬스 인코퍼레이티드 세로토닌-매개 질환 및 장애의 치료 방법
KR20150038726A (ko) 2007-06-26 2015-04-08 렉시컨 파마슈티컬스 인코퍼레이티드 트립토판 히드록실라제 억제제를 포함하는 조성물
CN101873852A (zh) 2007-09-27 2010-10-27 锐视医药公司 治疗视黄醇相关性疾病的方法和化合物
US7973079B2 (en) 2007-09-27 2011-07-05 Revision Therapeutics, Inc. Methods and compounds for treating retinol-related diseases
JP5374377B2 (ja) 2007-10-18 2013-12-25 武田薬品工業株式会社 複素環化合物
WO2009143390A2 (en) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc. Methods for modulating expression of rbp4
WO2009145286A1 (ja) * 2008-05-30 2009-12-03 武田薬品工業株式会社 複素環化合物
KR20120022927A (ko) * 2009-04-13 2012-03-12 아이알엠 엘엘씨 레티놀 결합 단백질 4 (ｒｂｐ4)에 대한 레티놀 결합을 조절하기 위한 조성물 및 방법
KR20120006545A (ko) * 2009-04-16 2012-01-18 다케다 야쿠힌 고교 가부시키가이샤 당뇨병의 예방 또는 치료에 특히 유용한 ｎ―아실―ｎ’―페닐피페라진의 유도체
WO2011059776A2 (en) 2009-10-28 2011-05-19 Revision Therapeutics, Inc Prophylaxis of skin cancer with retinamides
WO2011072275A2 (en) 2009-12-11 2011-06-16 Nono, Inc. Agents and methods for treating ischemic and other diseases
MX355038B (es) 2010-03-30 2018-03-28 Verseon Corp Compuestos aromáticos multisustituidos como inhibidores de trombina.
JP5951625B2 (ja) 2010-11-24 2016-07-13 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ 加齢性黄斑変性症およびシュタルガルト病の処置のための非レチノイドｒｂｐ４アンタゴニスト
TR201906779T4 (tr) 2011-05-12 2019-05-21 Proteostasis Therapeutics Inc Proteostaz regülatörleri.
GB201205679D0 (en) 2012-03-30 2012-05-16 Dyson Technology Ltd A hand held appliance
WO2013166041A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
US9580400B2 (en) 2013-02-26 2017-02-28 Northeastern University Cannabinergic nitrate esters and related analogs
WO2014160409A1 (en) 2013-03-14 2014-10-02 The Trustees Of Columbia University In The City Of New York Rbp4 antagonists for the treatment of age-related macular degeneration and stargardt disease
WO2014153643A1 (en) 2013-03-26 2014-10-02 The University Of British Columbia Compositions and methods for use thereof in the treatment of aniridia
JP2017508798A (ja) 2014-03-07 2017-03-30 ザ ジョンズ ホプキンス ユニバーシティ ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤
SG11201702312UA (en) 2014-10-24 2017-05-30 Takeda Pharmaceuticals Co Heterocyclic compound
MA47043B1 (fr) 2014-10-24 2021-09-30 Bristol Myers Squibb Co Composés indole carboxamides utiles comme inhibiteurs de kinase
CN107074804B (zh) 2014-10-24 2020-02-18 百时美施贵宝公司 咔唑衍生物
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use

Also Published As

Publication number Publication date
US10214498B2 (en) 2019-02-26
PH12017500747A1 (en) 2017-10-30
CA2965465A1 (en) 2016-04-28
ECSP17026687A (es) 2017-09-29
AU2020204426B2 (en) 2022-02-03
CA2965465C (en) 2023-08-01
JP2020007347A (ja) 2020-01-16
PE20170669A1 (es) 2017-06-06
JPWO2016063933A1 (ja) 2017-08-03
PH12017500747B1 (en) 2017-10-30
AU2015336480B2 (en) 2020-04-02
KR20170067791A (ko) 2017-06-16
IL285105B2 (en) 2023-03-01
MA39688B1 (fr) 2021-02-26
ZA201703344B (en) 2018-08-29
IL251695A0 (en) 2017-06-29
IL285105A (en) 2021-08-31
KR102490156B1 (ko) 2023-01-18
TN2017000097A1 (en) 2018-07-04
DK3210973T3 (da) 2021-02-08
CN107108506A (zh) 2017-08-29
SG11201702312UA (en) 2017-05-30
US20200157062A1 (en) 2020-05-21
JP6995094B2 (ja) 2022-02-21
EP3210973B1 (en) 2020-12-02
CY1123842T1 (el) 2022-05-27
PT3210973T (pt) 2021-02-12
CO2017003699A2 (es) 2017-07-28
PL3210973T3 (pl) 2021-06-28
TW202042805A (zh) 2020-12-01
RS61504B1 (sr) 2021-03-31
MX2021001188A (es) 2021-04-19
JP6588027B2 (ja) 2019-10-09
MA39688A (fr) 2017-08-30
US10975043B2 (en) 2021-04-13
EP3210973A4 (en) 2018-04-25
AU2015336480A2 (en) 2017-06-01
MY183209A (en) 2021-02-18
AU2015336480A1 (en) 2017-05-25
CN115197160A (zh) 2022-10-18
US20210340114A1 (en) 2021-11-04
EP3210973A1 (en) 2017-08-30
IL285105B (en) 2022-11-01
TW201714876A (zh) 2017-05-01
ES2848999T3 (es) 2021-08-13
CR20170160A (es) 2017-06-15
US20180237404A1 (en) 2018-08-23
EA033446B1 (ru) 2019-10-31
TWI749661B (zh) 2021-12-11
SI3210973T1 (sl) 2021-04-30
US20190119225A1 (en) 2019-04-25
MX2017004629A (es) 2017-06-30
HRP20210320T1 (hr) 2021-04-30
LT3210973T (lt) 2021-03-25
TWI703131B (zh) 2020-09-01
DOP2017000098A (es) 2017-07-15
WO2016063933A1 (ja) 2016-04-28
EA201790912A1 (ru) 2017-09-29
MA53568A (fr) 2022-02-23
US10544111B2 (en) 2020-01-28
AR104342A1 (es) 2017-07-12
UA121871C2 (uk) 2020-08-10
EP3848353A1 (en) 2021-07-14
AU2020204426A1 (en) 2020-07-23
CN107108506B (zh) 2022-06-21
BR112017007138A2 (pt) 2017-12-26
CL2017000944A1 (es) 2018-01-12
IL251695B (en) 2021-08-31
HUE053443T2 (hu) 2021-06-28

Similar Documents

Publication Publication Date Title
IL283561B (en) Methods for treating eye diseases
EP3212233A4 (en) Combination therapy for treatment of disease
HK1256795A1 (zh) 可用於治療自身免疫疾病的二吡唑基衍生物
PL3210973T3 (pl) Związki heteroarylowe do leczenia chorób oczu
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
HK1258994A1 (zh) 用於疾病治療的方法
HK1232220A1 (zh) 用於治療心血管疾病的 -苄基異喹啉衍生物
IL259297A (en) Heterocyclic compounds for the treatment of disease
GB2541840B (en) Ophthalmic composition for the treatment of ocular infection
ES3012058T3 (en) Compounds for the treatment of lipofuscin related diseases
IL259381B (en) Miravegron for the treatment of retinal diseases
PL3302463T3 (pl) Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu
EP3261635A4 (en) Compounds for treating ocular diseases